echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Epidiolex benefits from the u.S. list of controlled drugs in the U.S. for children in category 2 who have difficulty with treating epilepsy!

    Epidiolex benefits from the u.S. list of controlled drugs in the U.S. for children in category 2 who have difficulty with treating epilepsy!

    • Last Update: 2020-06-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    It comes after GW launched the world's first plant-derived cannabinoid prescription drug, sativex, which has been approved in many countries outside the U.Sto treat spasms for multiple sclerosis, and is pushing a late-stage project for Sativex to seek FDA approvalIt also includes a range of cannabinoid candidates, including compounds that treat epilepsy, autism, glioblastoma, and schizophreniaoriginal origin: GW Pharmaceuticals plc and Its U.SGroupy Greenwich Biosciences, IncThat's Announce EPIDIOLEX? (cannabidiol) Oral Solution Has Has Has Descheduled And Is No Longer A Control Substanceoriginal title: First new plant-sourced cannabinoid anti-epileptic drug! Epidiolex is removed from the list of controlled drugs in the United States, and 2 categories of children have difficulty with treating epilepsy benefits!
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.